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OBJECTIVES We sought to determine whether there was a relationship between serum digoxin concen-
tration (SDC), including SDCs typically regarded as low, and clinical efficacy related to
digoxin in patients with symptomatic left ventricular dysfunction.
BACKGROUND Digitalis glycosides have been used for 200 years in the treatment of heart failure (HF),
but the SDC required for optimal clinical efficacy and acceptable toxicity remains
controversial.
METHODS This relationship was investigated by utilizing data from two randomized, double-blinded,
placebo-controlled, digoxin-withdrawal trials: the Prospective Randomized study Of Ven-
tricular failure and Efficacy of Digoxin (PROVED) and the Randomized Assessment of
Digoxin on Inhibitors of Angiotensin-Converting Enzyme (RADIANCE). Major end points
were worsening HF, change in left ventricular ejection fraction and treadmill time after
randomization. The primary analysis investigated the relationship between SDC at randomization
and these end points. A secondary categorical analysis compared these end points in patients who
discontinued digoxin versus patients who continued digoxin and had low (0.5 to 0.9 ng/ml),
moderate (0.9 to 1.2 ng/ml) or high (1.2 ng/ml) SDCs at randomization.
RESULTS Multiple regression analysis failed to find a relationship between randomization SDC,
considered as a continuous variable, and any study end point (all p  0.236). Multivariable
Cox analysis found that the risk of worsening HF was significantly less (all p  0.02) for
patients in any category of SDC who continued digoxin, as compared with patients
withdrawn from digoxin. Specifically, patients in the low SDC category were significantly
less likely than placebo patients to experience worsening HF during follow-up (p 
0.018).
CONCLUSIONS The beneficial effects of digoxin on common clinical end points in patients with HF were
similar, regardless of SDC. (J Am Coll Cardiol 2002;39:946–53) © 2002 by the American
College of Cardiology Foundation
Digitalis glycosides have been used for 200 years in the
treatment of heart failure (HF), but the serum digoxin
concentration (SDC) required for optimal clinical efficacy
and acceptable toxicity remains controversial (1,2). Previous
work has established that higher serum concentrations exert
greater positive effects on left ventricular (LV) function
(3–6). However, the degree of improvement in LV func-
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tion, due to digitalis, necessary for a clinical benefit, if any,
is unknown. In addition, digitalis appears to exert a favor-
able effect on abnormalities of autonomic tone present in
HF, which calls into question a pure inotropic mechanism
of action for the drug (7,8). Recent work suggests these
favorable neurohormonal effects occur at low doses of
digoxin (9), and that increasing the SDC beyond modest
levels (i.e., 0.7 ng/ml) may not produce additional neuro-
hormonal benefits (10).
Despite suggestions from these mechanistic studies that
low SDCs might be as effective as higher ones, this work
contains few patients and does not provide convincing data
on end points of major clinical interest. To gain additional
insight into this issue, we applied the results from the
Prospective Randomized study Of Ventricular failure and
Efficacy of Digoxin (PROVED) and Randomized Assess-
ment of Digoxin on Inhibitors of the Angiotensin-
Converting Enzyme (RADIANCE) trials (11,12). These
randomized trials investigated the effect of digoxin with-
drawal on a number of important measures of clinical status,
including risk of worsening HF, exercise capacity and LV
function. Close monitoring revealed a spectrum of digoxin
concentrations in patients randomized to continue the drug
throughout follow-up, despite upward titration of the dose
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to achieve traditional therapeutic serum concentrations
during stabilization. Thus, the results from PROVED and
RADIANCE afford a unique opportunity to investigate
whether SDC is related to a clinical benefit from digoxin in
patients with HF. Our analysis provides significant new infor-
mation on administration of digoxin in patients with HF.
METHODS
Design of protocols. The design and conduct of the
PROVED and RADIANCE trials were similar, and the
details of these studies have been well documented in
previous reports (11,12). Briefly, both trials were multi-
center, double-blinded, randomized, placebo-controlled,
parallel-group, withdrawal studies that utilized the same
entry criteria (Fig. 1). Each study began with an eight-week,
single-blinded stabilization phase during which the patients’
background therapy for HF was optimized. Patients com-
pleting the baseline phase were randomized to either con-
tinue digoxin or receive placebo instead of digoxin, while
trial-specific background therapy was kept constant for as
long as possible during follow-up. After randomization, the
patients were reassessed in detail regarding their clinical
status, exercise capacity and ventricular function. Their
SDC was measured at visits 1, 4 and 6 in the baseline phase
and at the final study visit by a central laboratory (Smith-
Abbreviations and Acronyms
HF  heart failure
LV  left ventricular
LVEF  left ventricular ejection fraction
PROVED  Prospective Randomized study Of
Ventricular failure and Efficacy of
Digoxin
RADIANCE  Randomized Assessment of Digoxin on
Inhibitors of the Angiotensin-
Converting Enzyme
SDC  serum digoxin concentration
Figure 1. Study schema of the Prospective Randomized study Of Ventricular failure (PROVED) and Randomized Assessment of Digoxin on Inhibitors
of the Angiotensin-Converting Enzyme (RADIANCE) trials. After a period of single-blinded stabilization, the patients were randomized to continue or
discontinue digoxin, while maintaining background therapy as indicated. The occurrence of treatment failure was determined by an Events Committee that
was blinded to treatment assignment. ACEI  angiotensin-converting enzyme inhibitor; Chg Dig  investigator change in digoxin dose; CXR  chest
x-ray; Echo echocardiogram; ER emergency room; ETTmaximal exercise treadmill test; HF heart failure; Hx history; LVEF left ventricular
ejection fraction; NYHA  New York Heart Association functional class; PE  physical examination; SDC  serum digoxin concentration; Wk  week;
6 MinWalk  6-min walk test.
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Kline BioScience). The dose of digoxin was withheld on the
day of these protocol visits, so that serum concentrations
reflected trough levels of digoxin. Digoxin dose adjustments
were made, based on the determination at visit 1, in an
attempt to achieve an SDC of 0.9 to 2.0 ng/ml by the time
of randomization. Digoxin doses were to remain unchanged
after randomization, and SDC was measured in a similar
fashion at the final study visit.
Analysis of end points. Data from the PROVED and
RADIANCE trials were combined for the purposes of this
analysis. Both PROVED and RADIANCE compared pa-
tients randomized to continue or discontinue digoxin, with
regard to the following end points: 1) rates of withdrawal
due to worsening HF; 2) time to withdrawal; and 3) changes
in exercise capacity, as assessed by treadmill testing or the
6-min walk test. In the present analysis, end points 1 and 2
were evaluated and end point 3, analysis of exercise capacity,
was restricted to treadmill data. In addition, we compared
the change in LV ejection fraction (LVEF) from random-
ization to the last measured value in the study patients.
Statistical analysis. The patient populations of PROVED
and RADIANCE were combined for the study analysis.
Data are presented as the mean value  SEM, unless
otherwise indicated. In the principal study analysis, multi-
variate modeling was used to assess the relationship between
SDC at randomization and end points of major interest.
Treatment failure was assessed using Cox proportional
hazards methods, and change in treadmill exercise capacity
and LVEF were assessed by standard multiple regression
(13). The following variables were considered as potential
predictors of the study end points of interest: the last
available SDC at or before randomization, race, age, gender,
ischemic versus nonischemic etiology, use of angiotensin-
converting enzyme inhibitors, blood pressure, heart rate,
jugular venous distension, S3 gallop, rest LVEF, cardiotho-
racic ratio, exercise tolerance, LV end-diastolic dimension
and HF score. The HF score was determined from the
patient’s symptoms, signs and chest x-ray results collected at
the randomization visit, as previously described (14). In
addition, digoxin use after randomization was included as a
categorical variable to model the effect of digoxin therapy
versus no digoxin therapy, regardless of the magnitude of
SDC at randomization. Finally, regression analysis was
repeated using the final SDC obtained after randomization.
A secondary categorical analysis was performed to assess
the relationship between SDC and specific study end points.
For this analysis, patients were divided into four subgroups:
1) patients randomized to discontinue digoxin, regardless of
SDC at randomization; 2) patients who continued digoxin
and were found at randomization to have an SDC in the
lowest tertile (33 percentile; 0.9 ng/ml); 3) middle
tertile (33 to 66 percentile; 0.9 to 1.2 ng/ml); and 4) highest
tertile (66 percentile; 1.2 ng/ml) at randomization. In
this analysis, assessment of the relationship between SDC
subgroups and study end points was made by Cox propor-
tional hazards methods for treatment failure and by appro-
priate parametric and nonparametric tests for changes in
treadmill exercise capacity and LVEF.
RESULTS
Study patients. Table 1 summarizes the clinical character-
istics of the PROVED and RADIANCE patient popula-
tions classified into treatment groups based on their SDC at
randomization versus patients randomized to discontinue
digoxin. These four subgroups of patients from PROVED
and RADIANCE had comparable baseline characteristics.
Digoxin dose and SDC. The average daily dose of digoxin
was 0.22  0.01 mg/day at the baseline visit, which was
associated with a mean SDC of 0.60  0.04 ng/ml. During
the baseline phase, there was an upward titration of the
digoxin dose to 0.36  0.01 mg/day, which was associated
with a mean SDC of 1.11  0.02 ng/ml by the random-
ization visit. Only trivial changes in the dose of digoxin were
noted among the 77 patients randomized to continue
digoxin who had this result available at their final visit. The
final mean digoxin dose for these patients was 0.37 
0.01 mg/day. Data on SDC at the final visit were available
in 116 of the 127 patients randomized to continue digoxin
and were very similar to the randomization SDC data for
the entire group (1.13 0.05 ng/ml). Data in Table 2 show
the mean digoxin dose at baseline, randomization and the
final study visit for the four subgroups of SDC. The mean
values were similar from randomization to the final study
visit for the digoxin dose and SDC in each of the four
treatment groups.
Multiple regression analysis. Multivariable Cox modeling
of the likelihood of treatment failure after randomization
failed to associate SDC at randomization with this end
point (relative risk [RR] 1.72, 95% confidence interval [CI]
0.70 to 4.22, p  0.236). In contrast, there was a strong
relationship between continuing or discontinuing digoxin
and the occurrence of treatment failure after randomization
(RR 0.15 for digoxin vs. no digoxin, 95% CI 0.07 to 0.32,
p  0.0001). Likewise, a change in the treadmill duration
was not associated with SDC at randomization (p  0.855)
but was significantly related to whether the patient contin-
ued or discontinued digoxin during follow-up (p 0.0001).
There was no relationship between SDC at randomization
and a change in LVEF (p 0.274), whereas randomization
to digoxin or placebo was significantly related to a change in
LVEF (p 0.0001). Multiple regression analysis also failed
to find a relationship between final SDC and any end point
considered in this analysis (all p  0.578).
Categorical analysis. There was no difference between
subgroups with low, moderate or high SDCs at randomiza-
tion, with respect to developing worsening HF during the
12-week follow-up period. A total of 41 patients (30%)
experienced worsening HF during follow-up in the placebo
group. The incidence of worsening HF during follow-up
was similar in the SDC groups: 6% (n  2) for the group
with a randomization SDC between 0.5 and 0.9 ng/ml
948 Adams et al. JACC Vol. 39, No. 6, 2002
Serum Digoxin Concentration and Efficacy March 20, 2002:946–53
versus 9% (n  4) in the group with SDC values between
0.9 and 1.2 ng/ml and 12% (n  6) in the group with
SDC 1.2 ng/ml (p  0.05). Unadjusted Cox proportional
hazards analysis of the follow-up data demonstrated that the
risk of treatment failure was significantly greater for patients
withdrawn from digoxin therapy (p  0.030), compared
with patients who continued digoxin in any of the three
randomization SDC groups. Multivariable Cox analysis
demonstrated that the risk of worsening HF was signifi-
cantly less (all p  0.020) for all subgroups of patients who
continued digoxin after adjustment for LVEF, cardiotho-
racic ratio, age, HF score and angiotensin-converting en-
zyme inhibitor use (Table 3, Fig. 2). Specifically, patients in
the low SDC category were significantly less likely than
placebo patients to experience worsening HF during
follow-up (p  0.018). A similar analysis, which added
distance walked in 6 min at baseline to the previous model,
also demonstrated that the risk of worsening HF was
significantly less for patients randomized to continue
digoxin, regardless of SDC at randomization (all p 
0.020).
Median changes in maximal treadmill exercise time
during follow-up in the various SDC subgroups are shown
in Figure 3. After 12 weeks, patients continuing digoxin in
the lowest SDC group at randomization had a significantly
greater change (median 5.5 s) in exercise time, compared
with patients withdrawn from digoxin (median 46 s, p 
0.015). A median change in exercise capacity was similar
after 12 weeks among patients in the low (5.5 s), moderate
(33 s) and high (1 s) SDC groups (all p  0.078).
Table 1. Baseline Clinical Characteristics: Digoxin Withdrawal Versus Digoxin Continuation by
Tertile of SDC Before Randomization
Characteristic
All Digoxin WD/
Any SDC
Digoxin Continuation
p Value<0.9 ng/ml >0.9–1.2 ng/ml >1.2 ng/ml
Gender
Male 113 (81%) 27 (84%) 33 (75%) 38 (75%) 0.562
Female 26 (19%) 5 (16%) 11 (25%) 13 (25%)
NYHA functional class
I 3 (2%) 1 (3%) 2 (5%) 0.093
II 106 (76%) 26 (81%) 27 (61%) 39 (76%)
III 30 (22%) 4 (13%) 15 (34%) 12 (24%)
Primary etiology
IHD 83 (60%) 19 (59%) 31 (70%) 30 (59%) 0.597
Non-IHD 56 (40%) 13 (41%) 13 (30%) 21 (41%)
Age (yrs) 61  1.0 61  2.2 62  1.6 65  1.4 0.383
SDC (ng/ml) 1.1  0.03 0.8  0.02 1.1  0.08 1.5  0.03 0.001
LVEF (U) 28  0.8 29  2.2 24  1.4 26  1.6 0.085
CT ratio 0.53  0.01 0.52  0.01 0.54  0.01 0.54  0.01 0.438
Duration of HF (yrs) 3.5  0.4 3.7  0.7 4.1  0.6 4.9  0.6 0.242
Supine systolic blood pressure
(mm Hg)
126  1.5 128  3.6 125  2.7 127  2.2 0.643
Supine pulse (beats/min) 76  1.1 76  1.9 77  1.9 74  1.9 0.798
Exercise duration (s) 542 524 491 414 0.220
6-minute walk (ft) 1,155 1,087 1,190 1,080 0.751
P values reflect the results of analysis of variance statistics comparing the four therapeutic groups. Data are presented as the
number (%) of patients, mean value  SEM or median value.
CT  cardiothoracic; HF  heart failure; IHD  ischemic heart disease; LVEF  left ventricular ejection fraction;
NYHA  New York Heart Association; SDC  serum digoxin concentration; WD  withdrawal.
Table 2. Digoxin Dosages and Corresponding SDCs in the Study Treatment Groups
Time Point
All Digoxin WD/
Any SDC
Digoxin Continuation
<0.9 ng/ml >0.9–1.2 ng/ml >1.2 ng/ml
Dose
(mg/day)
SDC
(ng/ml)
Dose
(mg/day)
SDC
(ng/ml)
Dose
(mg/day)
SDC
(ng/ml)
Dose
(mg/day)
SDC
(ng/ml)
Baseline* 0.21  0.01 0.54  0.06 0.22  0.01 0.45  0.11 0.23  0.01 0.69  0.08 0.22  0.01 0.78  0.12
Before randomization† 0.37  0.01 1.11  0.03 0.38  0.02 0.78  0.02 0.37  0.02 1.09  0.01 0.34  0.02 1.52  0.03
Change from baseline to
pre-randomization
0.15  0.01 0.57  0.06 0.16  0.02 0.33  0.10 0.14  0.01 0.40  0.08 0.13  0.01 0.73  0.12
End point — — 0.42  0.02 0.90  0.04 0.40  0.03 1.14  0.09 0.39  0.03 1.25  0.08
Change from
pre-randomization to
end point
— — 0.01  0.01 0.13  0.04 0.04  0.02 0.05  0.09 0.01  0.01 0.28  0.08
*At visit 1. †At visit 6. Treatment groups were classified by the pre-randomization serum digoxin concentration. Data are presented as the mean value  SEM.
SDC  serum digoxin concentration; WD  withdrawal.
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The change in LVEF from randomization to the last
measured value for each of the four subgroups of SDC is
shown in Figure 4. The change in LVEF for those patients
who continued the drug was similar, regardless of SDC at
randomization. Left ventricular ejection fraction declined
significantly in patients withdrawn from digoxin (4.1 
0.7 U), compared with patients who continued digoxin in
the low (1.4  1.1 U), moderate (1.2  1.1 U) or high
serum (0.0  1.2 U) SDC groups (all p  0.005).
DISCUSSION
Although substantial evidence for a benefit of digoxin in
patients with HF has accumulated over two centuries of use,
culminating in the recent results of the study done by the
Digitalis Investigation Group (15), previous work has not
defined the SDC necessary for clinical efficacy. Our results,
derived from the PROVED and RADIANCE trials, pro-
vide important new information on the serum concentration
necessary for a therapeutic benefit in patients with HF. Our
principal analysis failed to demonstrate any significant
relationship between SDC, as a continuous variable, and the
clinical outcomes of patients in PROVED and RADIANCE.
Patients taking digoxin did significantly better than those
not taking the drug, but the serum concentration did not
correlate with the outcome. This finding was confirmed by
our secondary categorical analysis, which revealed favorable
outcomes in patients treated with relatively low SDCs
(0.9 ng/ml). Patients who continued digoxin in this range
of serum concentrations had a similar risk of treatment
failure and similar exercise capacity and maintained their
LVEF, as well as patients who continued digoxin at higher
serum concentrations. The lack of a relationship between
LV function and SDC was anticipated, given the serum
concentrations present in the patients in PROVED and
RADIANCE and the previous results of dose-response
studies of the effects of digoxin on LV function. However,
and more importantly, the clinical outcomes of treadmill
performance and risk of worsening HF in patients who
continued digoxin were independent of the serum concen-
tration, as well, and were superior in the categorical analysis
of all specific SDC groups compared with the group
Table 3. Risk of Treatment Failure Based on Randomization
SDC Group
Treatment
Group
Relative
Risk 95% CI p Value
Digoxin continued (SDC)
0.9 ng/ml 0.09 0.01–0.66 0.018
0.9–1.2 ng/ml 0.22 0.08–0.61 0.004
1.2 ng/ml 0.17 0.06–0.44 0.001
Relative risk and p values are based on the adjusted Cox proportional hazards analysis.
CI  confidence interval; SDC  serum digoxin concentration.
Figure 2. Adjusted likelihood of worsening heart failure (HF) in the four patient groups defined by either withdrawal from digoxin or serum digoxin
concentration (SDC) at randomization in those who continued the drug. Patients who continued digoxin in any category of serum concentration were
significantly less likely (all p  0.02) to experience treatment failure than patients withdrawn from digoxin.
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withdrawn from digoxin. The absence of a significant
relationship between clinical efficacy and SDC was also
found when continuous or categorical analyses were per-
formed utilizing the serum concentration determined at the
final study visit.
Previous studies. Recommendations for target SDCs ap-
pear to have been originally derived from dose-response
studies of the effect of digoxin on various indexes of
ventricular function (16). Noninvasive indexes suggest an
increase in ventricular function up to a steady-state serum
Figure 3. Changes in maximal exercise treadmill test (ETT) duration in the four patient groups analyzed in the study. At the end of 12 weeks, patients
who continued digoxin in each of the serum concentration groups had a significantly better exercise capacity than patients who discontinued digoxin (*p
value for all three serum digoxin groups vs. placebo [digoxin withdrawal]). SDC  serum digoxin concentration.
Figure 4. Changes in left ventricular ejection fraction (LVEF) from randomization to the final study measurement in the four patient groups analyzed in
the study. Left ventricular ejection fraction declined significantly in patients who discontinued digoxin (Dig), compared with patients who continued
digoxin, regardless of the serum concentration at randomization (*all p  0.005). SDC  serum digoxin concentration.
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concentration of 1.4 ng/ml, with little or no further
improvement as the serum concentration rises above this
level (3–6). Increasing recognition that neurohormonal
modulation is related to the clinical efficacy of digoxin
suggests that dose-response relationships for this action
should be considered, as well (17). Two recent studies
provide important additional data on dose-response rela-
tionships for both ventricular function and the
neurohormonal-modulating effects of digoxin. Gheorghiade
et al. (10) demonstrated an increase of 3.5 U in LVEF as
SDC rose from 0.67 22 ng/ml to 1.22 0.35 ng/ml, with
increasing oral doses of digoxin in 22 patients with HF due
to systolic dysfunction. This increase in LVEF was not
accompanied by any change in HF score, exercise tolerance
or plasma norepinephrine concentration. These results sug-
gest a dissociation between the effects of digoxin on LV
function and the neurohormonal actions of the drug. Slatton
et al. (9) studied the short-term (two-week) effects of low
(0.125 mg/day) and moderate (0.25 mg/day) doses of
digoxin on indexes of LV function and neurohormonal
status in 19 patients with moderate clinical HF and LVEF
0.45. Although data on the serum concentration were not
reported, these investigators found that low-dose digoxin
therapy increased ventricular performance, reduced the heart
rate and increased heart rate variability. An increase to
moderate-dose digoxin did not further reduce sympathetic
activity, as assessed by heart rate variability or plasma norepi-
nephrine concentration. Interestingly, these investigators dem-
onstrated an increase in ventricular performance by several
relatively load-independent indexes with low-dose digoxin and
no further increase with moderate-dose digoxin. These two
recent studies support the findings of the present study con-
cerning the efficacy of low serum concentrations of digoxin.
Therapeutic considerations. Sudden death, most com-
monly due to presumed rapid ventricular arrhythmia, re-
mains an important unresolved problem of patients with
chronic HF (18). Despite beneficial hemodynamic effects,
inotropic therapy for HF has been associated with an
adverse effect on mortality, which appears to be related to an
increased risk of sudden death. Data from several clinical
trials support the concept that the increased risk of sudden
death is dose-dependent—more likely to occur at higher
doses (19–21). A similar analysis is under way for digoxin,
based on the Digitalis Investigation Group’s data, but has
not yet been published. However, data already suggest that
SDC 1 ng/ml may be associated with classic digoxin
toxicity (22–25). In addition, the findings of Williamson et
al. (26) indicate that serum digoxin levels 2.0 ng/ml still
occur with some frequency (9.3%) in clinical practice and
cannot be attributed solely to sampling too close to the daily
dose of digoxin. Results from our study and previous work
reviewed by others (27) suggest that SDCs classically consid-
ered to be low are, in fact, effective in patients with HF due to
systolic dysfunction. Hopefully, the use of doses of digoxin to
achieve serum concentrations 0.9 ng/ml will be associated
with reduced toxicity, as well as favorable clinical effects.
Study limitations. A prospective, randomized trial of doses
designed to achieve various SDCs will be necessary to
definitively establish the dose-response efficacy of digoxin in
patients with HF. Patients who continued digoxin therapy
in our study were not randomly assigned to predetermined
SDC groups. This meant that a prospective determination
of specific ranges of SDC for comparison was not possible,
and that patients in different ranges of SDC may have been
different at baseline. However, our principal analysis mod-
eled SDC as a continuous variable to avoid the potential
bias introduced by selection of arbitrary cut points. The
results of our continuous analysis were subsequently con-
firmed by a secondary categorical analysis, based on specific
subgroups of SDC defined by randomization values. In
addition, patients in the various SDC subgroups were found
to be similar with regard to a number of baseline charac-
teristics evaluated. Multivariate analysis, which adjusted for
several baseline characteristics that might have influenced
the likelihood of treatment failure, demonstrated that pa-
tients in the lowest serum digoxin tertile, defined either by
randomization or final study visit values, had a significantly
lower risk of treatment failure, compared with patients
withdrawn from digoxin.
The PROVED and RADIANCE trials had a withdrawal
design. Withdrawal trials are inherently less rigorous tests of
efficacy, compared with studies in which the drug being
investigated is prospectively added at randomization. Inter-
estingly, the results from the Digitalis Intervention Group
trial, which enrolled patients both receiving (subsequent
withdrawal subset) and not receiving digoxin (subsequent
add-on subset) at baseline, support the overall efficacy
findings demonstrated in PROVED and RADIANCE.
The estimate of a clinical benefit from digoxin compared
with placebo was similar among patients not taking digoxin
at baseline (patients who had digoxin added did better than
those who did not) and among patients who were taking
digoxin at baseline (patients who continued digoxin did
better than those who were withdrawn) (15).
Conclusions. In severe, symptomatic systolic dysfunction,
evidence of a benefit from digoxin therapy was apparent,
regardless of SDC. A secondary categorical analysis also
demonstrated similar outcomes in patients who continued
digoxin at low, moderate and high SDCs, compared with
patients withdrawn from digoxin. These results support the
possibility that a lower therapeutic goal for SDC is war-
ranted in patients with HF.
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